Great Lakes Advisors LLC Takes Position in Incyte Co. (INCY)

Great Lakes Advisors LLC acquired a new stake in Incyte Co. (NASDAQ:INCY) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,504 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors also recently modified their holdings of INCY. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 22 shares during the period. IFP Advisors Inc increased its position in shares of Incyte by 6.8% in the first quarter. IFP Advisors Inc now owns 1,043 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 66 shares during the period. Howard Hughes Medical Institute increased its position in shares of Incyte by 42.2% in the first quarter. Howard Hughes Medical Institute now owns 1,210 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 359 shares during the period. Douglass Winthrop Advisors LLC acquired a new position in shares of Incyte during the first quarter valued at $201,000. Finally, Norris Perne & French LLP MI acquired a new position in shares of Incyte during the first quarter valued at $201,000. Hedge funds and other institutional investors own 92.62% of the company’s stock.

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) opened at 138.10 on Thursday. The firm has a 50-day moving average of $126.82 and a 200-day moving average of $120.55. Incyte Co. has a one year low of $71.75 and a one year high of $153.15. The firm’s market cap is $28.28 billion.

Incyte (NASDAQ:INCY) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The business had revenue of $384.08 million for the quarter, compared to analyst estimates of $359.19 million. During the same period last year, the business posted $0.12 EPS. Incyte’s revenue was up 45.8% compared to the same quarter last year. Analysts anticipate that Incyte Co. will post ($0.76) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Great Lakes Advisors LLC Takes Position in Incyte Co. (INCY)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://sportsperspectives.com/2017/05/25/great-lakes-advisors-llc-takes-position-in-incyte-co-incy.html.

INCY has been the subject of several analyst reports. TheStreet upgraded Incyte from a “c” rating to a “b-” rating in a report on Tuesday, February 14th. Goldman Sachs Group Inc boosted their price target on Incyte from $116.00 to $149.00 and gave the company a “buy” rating in a report on Friday, January 27th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $136.00 price target on shares of Incyte in a report on Thursday, February 16th. Jefferies Group LLC boosted their price target on Incyte from $136.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, February 15th. Finally, Instinet initiated coverage on Incyte in a report on Wednesday, March 1st. They issued a “buy” rating and a $148.00 price target for the company. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Incyte has a consensus rating of “Buy” and a consensus target price of $139.93.

In other Incyte news, Director Paul A. Friedman sold 50,000 shares of the firm’s stock in a transaction on Friday, March 17th. The shares were sold at an average price of $148.72, for a total value of $7,436,000.00. Following the sale, the director now directly owns 302,976 shares in the company, valued at approximately $45,058,590.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime purchased 500 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was bought at an average price of $115.00 per share, for a total transaction of $57,500.00. Following the completion of the transaction, the director now directly owns 4,177 shares in the company, valued at $480,355. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 3,000 shares of company stock worth $398,770 and sold 137,968 shares worth $19,395,245. Company insiders own 13.70% of the company’s stock.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

12 Month Chart for NASDAQ:INCY

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply